In the present study, we reported for the first time an AML patient with <i>RUNX1-RUNX1T1</i> who underwent preemptive treatment with the combined application of tislelizumab (an anti-PD-1 antibody) and azacitidine to avoid HR following allo-HSCT. The gene discussed is RUNX1T1; the disease is acute myeloid leukemia.